Related Experiment Video

Updated: Sep 19, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

[Fusarium pleural effusion after a ventricular assist device]

J Villacorta1, A Blancard, F Kerbaul

  • 1Département d'anesthésie-réanimation Adultes, CHU Timone, 264, rue Saint-Pierre, 13385 Marseille, Paris, France. jvillacortatorres@mail.ap-hm.fr

Annales Francaises D'Anesthesie Et De Reanimation
|June 25, 2002
PubMed

Insights

A rare Fusarium infection complicated a patient's recovery after ventricular assist device (VAD) implantation. Successful treatment involved liposomal amphotericin B and 5-fluorocytosine, leading to complete recovery.

Area of Science:

  • Medicine
  • Infectious Diseases
  • Cardiology

Background:

  • Ventricular assist devices (VADs) are crucial for end-stage heart failure management.
  • Postoperative complications, including infections, can arise after VAD implantation.
  • Fungal infections, though rare, pose a significant threat in immunocompromised patients.

Observation:

  • A 36-year-old male developed a pleural effusion post-VAD surgery.
  • The effusion was diagnosed as a Fusarium infection, a rare but serious complication.
  • This case highlights the potential for invasive fungal infections in VAD recipients.

Findings:

  • Epidemiological, etiologic, and therapeutic aspects of Fusarium infections were reviewed.
  • The patient received treatment with liposomal amphotericin B (AmBisome) and 5-fluorocytosine.
  • Complete resolution of the Fusarium infection was achieved with this combination therapy.

Implications:

  • This case underscores the importance of considering rare fungal pathogens in VAD-related infections.
  • Effective treatment strategies for Fusarium infections in VAD patients can be established.
  • Early diagnosis and prompt, aggressive antifungal therapy are critical for favorable outcomes in VAD recipients.

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Related Concept Videos

Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Pleural Effusion I: Introduction01:25

Pleural Effusion I: Introduction

Pleural effusion is an abnormal fluid accumulation in the pleural cavity, a narrow space between the lungs and the chest wall. It is not a disease per se but rather a symptom or indication of an underlying disease. In normal circumstances, this space contains a small amount of fluid (5 to 15 mL), a lubricant facilitating the non-frictional movement of the pleural surfaces.
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's criteria,...
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Pulmonary Edema II: Pathophysiology01:18

Pulmonary Edema II: Pathophysiology

Pulmonary edema is the accumulation of fluid in the interstitial and alveolar spaces of the lungs, impairing gas exchange and oxygen delivery. It may be cardiogenic or noncardiogenic, but both reduce oxygenation and lung compliance.Cardiogenic Pulmonary EdemaCardiogenic edema results from increased hydrostatic pressure in pulmonary capillaries, usually due to left ventricular dysfunction from myocardial infarction, heart failure, or valvular disease. Ineffective cardiac pumping causes blood to...